Current Pharmacologic Management in Selected Neuromuscular Diseases

Andrew J. Skalsky, Bjorn E Oskarsson, Jay J. Han, David P Richman

Research output: Contribution to journalArticle

Abstract

For generations, the neuromuscular disorder care community has focused on establishing the correct diagnosis and providing supportive care. As the pathophysiology and genetics of these conditions became better understood, novel treatments targeting the disease mechanism were developed. This has led to some significant disease-modifying and supportive treatments for several neuromuscular disorders. The current treatments for amyotrophic lateral sclerosis (ALS), neuromuscular junction disorders, inflammatory myopathies, and myotonia are reviewed. Additionally, investigational treatments for ALS, Duchenne muscular dystrophy, and spinal muscular atrophy are discussed.

Original languageEnglish (US)
Pages (from-to)801-820
Number of pages20
JournalPhysical Medicine and Rehabilitation Clinics of North America
Volume23
Issue number4
DOIs
StatePublished - Nov 2012

Fingerprint

Neuromuscular Diseases
Amyotrophic Lateral Sclerosis
Neuromuscular Junction Diseases
Myotonia
Spinal Muscular Atrophy
Investigational Therapies
Myositis
Duchenne Muscular Dystrophy
Therapeutics

Keywords

  • Amyotrophic lateral sclerosis
  • Duchenne muscular dystrophy
  • Inflammatory myopathy
  • Myasthenia gravis
  • Myotonia
  • Spinal muscular atrophy

ASJC Scopus subject areas

  • Rehabilitation
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Current Pharmacologic Management in Selected Neuromuscular Diseases. / Skalsky, Andrew J.; Oskarsson, Bjorn E; Han, Jay J.; Richman, David P.

In: Physical Medicine and Rehabilitation Clinics of North America, Vol. 23, No. 4, 11.2012, p. 801-820.

Research output: Contribution to journalArticle

Skalsky, Andrew J. ; Oskarsson, Bjorn E ; Han, Jay J. ; Richman, David P. / Current Pharmacologic Management in Selected Neuromuscular Diseases. In: Physical Medicine and Rehabilitation Clinics of North America. 2012 ; Vol. 23, No. 4. pp. 801-820.
@article{626e57e7da8947e79e076b76ca824b54,
title = "Current Pharmacologic Management in Selected Neuromuscular Diseases",
abstract = "For generations, the neuromuscular disorder care community has focused on establishing the correct diagnosis and providing supportive care. As the pathophysiology and genetics of these conditions became better understood, novel treatments targeting the disease mechanism were developed. This has led to some significant disease-modifying and supportive treatments for several neuromuscular disorders. The current treatments for amyotrophic lateral sclerosis (ALS), neuromuscular junction disorders, inflammatory myopathies, and myotonia are reviewed. Additionally, investigational treatments for ALS, Duchenne muscular dystrophy, and spinal muscular atrophy are discussed.",
keywords = "Amyotrophic lateral sclerosis, Duchenne muscular dystrophy, Inflammatory myopathy, Myasthenia gravis, Myotonia, Spinal muscular atrophy",
author = "Skalsky, {Andrew J.} and Oskarsson, {Bjorn E} and Han, {Jay J.} and Richman, {David P}",
year = "2012",
month = "11",
doi = "10.1016/j.pmr.2012.09.003",
language = "English (US)",
volume = "23",
pages = "801--820",
journal = "Physical Medicine and Rehabilitation Clinics of North America",
issn = "1047-9651",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Current Pharmacologic Management in Selected Neuromuscular Diseases

AU - Skalsky, Andrew J.

AU - Oskarsson, Bjorn E

AU - Han, Jay J.

AU - Richman, David P

PY - 2012/11

Y1 - 2012/11

N2 - For generations, the neuromuscular disorder care community has focused on establishing the correct diagnosis and providing supportive care. As the pathophysiology and genetics of these conditions became better understood, novel treatments targeting the disease mechanism were developed. This has led to some significant disease-modifying and supportive treatments for several neuromuscular disorders. The current treatments for amyotrophic lateral sclerosis (ALS), neuromuscular junction disorders, inflammatory myopathies, and myotonia are reviewed. Additionally, investigational treatments for ALS, Duchenne muscular dystrophy, and spinal muscular atrophy are discussed.

AB - For generations, the neuromuscular disorder care community has focused on establishing the correct diagnosis and providing supportive care. As the pathophysiology and genetics of these conditions became better understood, novel treatments targeting the disease mechanism were developed. This has led to some significant disease-modifying and supportive treatments for several neuromuscular disorders. The current treatments for amyotrophic lateral sclerosis (ALS), neuromuscular junction disorders, inflammatory myopathies, and myotonia are reviewed. Additionally, investigational treatments for ALS, Duchenne muscular dystrophy, and spinal muscular atrophy are discussed.

KW - Amyotrophic lateral sclerosis

KW - Duchenne muscular dystrophy

KW - Inflammatory myopathy

KW - Myasthenia gravis

KW - Myotonia

KW - Spinal muscular atrophy

UR - http://www.scopus.com/inward/record.url?scp=84868359022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868359022&partnerID=8YFLogxK

U2 - 10.1016/j.pmr.2012.09.003

DO - 10.1016/j.pmr.2012.09.003

M3 - Article

C2 - 23137738

AN - SCOPUS:84868359022

VL - 23

SP - 801

EP - 820

JO - Physical Medicine and Rehabilitation Clinics of North America

JF - Physical Medicine and Rehabilitation Clinics of North America

SN - 1047-9651

IS - 4

ER -